Cover Image
Market Research Report

North America Drug Delivery Market - Industry Trends and Forecast to 2027

Published by Data Bridge Market Research Private Limited Product code 536506
Published Content info 100 Pages
Delivery time: 1-2 business days
Price
Back to Top
North America Drug Delivery Market - Industry Trends and Forecast to 2027
Published: March 1, 2020 Content info: 100 Pages
Description

North America drug delivery market is projected to register a substantial growth in the forecast period of 2020 to 2027. The new market report contains data for historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.

Market Segmentation

North America Drug Delivery Market, By Product Type (Oral Drug Delivery, Pulmonary Drug Delivery, Injectable Drug Delivery, Opthalmic Drug Delivery, Nasal Drug Delivery, Topical Drug Delivery, Implantable Drug Delivery, Transmucosal Drug Delivery), End User (Hospitals, Community Healthcare, Home Healthcare, Clinics, Others), Distribution Channel (Hospital Pharmacies, Pharmacy Stores, Direct Tenders, Online Pharmacy), Country (U.S., Mexico, Canada), Market Trends and Forecast to 2027

Some of the major factors contributing to the growth of the North America drug delivery market are:

  • Rising acceptance of self-administering drugs
  • Increasing awareness about diagnosis and treatment

Market Players

The Key Market Players for North America drug delivery market are listed below:

  • Johnson & Johnson services, Inc.
  • Novartis AG
  • F. Hoffmann-la Roche Ltd
  • Bayer AG
  • Pfizer Inc.
  • 3M
  • Antares Pharma
  • GlaxoSmithKline Plc
  • Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.)
  • Nemera
  • Sanofi
Table of Contents

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF NORTH AMERICA DRUG DELIVERY MARKET
  • 1.4 LIMITATIONS
  • 1.5 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 CURRENCY AND PRICING
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL
  • 2.6 MULTIVARIATE MODELLING
  • 2.7 PRODUCTS LIFELINE CURVE
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.9 DBMR MARKET POSITION GRID
  • 2.10 VENDOR SHARE ANALYSIS
  • 2.11 SECONDARY SOURCES
  • 2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW

  • 5.1 DRIVERS
    • 5.1.1 RISING PREVALENCE OF CHRONIC DISEASE AND NON CHRONIC DISEASE
    • 5.1.2 GROWTH IN THE DEVELOPMENT OF BIOLOGICS
    • 5.1.3 TECHNOLOGICAL DEVELOPMENT
    • 5.1.4 INCREASING AWARENESS ABOUT DIAGNOSIS AND TREATMENT
    • 5.1.5 RISING ACCEPTANCE OF SELF ADMINISTERING DRUGS
  • 5.2 RESTRAINTS
    • 5.2.1 RISK OF NEEDLE-STICK INJURIES AND SIDE EFFECTS
    • 5.2.2 HIGH COSTS OF DRUGS
    • 5.2.3 STRINGENT REGULATORY SCENARIO
    • 5.2.4 PRODUCT RECALLS

  • 5.3 OPPORTUNITIES
    • 5.3.1 RISING DEMAND FOR BIOSIMILARS AND GENERIC DRUGS
    • 5.3.2 THERAPEUTIC ADVANCEMENTS
    • 5.3.3 TREND OF MERGER AND ACQUISITIONS AND COLLABORATIONS
    • 5.3.4 FOCUS ON PATIENTS' NEEDS
    • 5.3.5 DEVELOPING AND NEW EMERGING REVENUE POCKETS
  • 5.4 CHALLENGES
    • 5.4.1 SIDE EFFECTS OF DRUG DELIVERY SYSTEMS
    • 5.4.2 PATENT EXPIRY AND PATENT CLIFF
    • 5.4.3 ALTERNATIVES TO DRUG DELIVERY

6 NORTH AMERICA DRUG DELIVERY MARKET, BY PRODUCT TYPE

  • 6.1 OVERVIEW
  • 6.2 ORAL DRUG DELIVERY
    • 6.2.1 BY FORM
      • 6.2.1.1 SOLID ORAL DRUGS
        • 6.2.1.1.1 TABLETS
        • 6.2.1.1.2 CAPSULES
        • 6.2.1.1.3 PILLS
        • 6.2.1.1.4 POWDERS
      • 6.2.1.2 LIQUID ORAL DRUGS
        • 6.2.1.2.1 SYRUPS
        • 6.2.1.2.2 SOLUTIONS
      • 6.2.1.3 semi solid oral drugs
        • 6.2.1.3.1 GELS
        • 6.2.1.3.2 EMULSIONS
        • 6.2.1.3.3 ELIXIRS
  • 6.3 INJECTABLE DRUG DELIVERY
    • 6.3.1 INJECTABLE DRUG DELIVERY DEVICES
      • 6.3.1.1 CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES
        • 6.3.1.1.1 BY MATERIAL TYPE
        • 6.3.1.1.1.1 GLASS
        • 6.3.1.1.1.2 PLASTIC
        • 6.3.1.1.2 BY PRODUCT TYPE
        • 6.3.1.1.2.1 FILLABLE
        • 6.3.1.1.2.2 PRE-FILLED
        • 6.3.1.1.3 BY USABILITY
        • 6.3.1.1.3.1 REUSABLE SYRINGES
        • 6.3.1.1.3.2 DISPOSABLE SYRINGES

      • 6.3.1.2 SELF-INJECTION DRUG DELIVERY
        • 6.3.1.2.1 NEEDLE FREE INJECTORS
        • 6.3.1.2.2 WEARABLE INJECTORS
        • 6.3.1.2.3 PEN INJECTOR
        • 6.3.1.2.4 AUTO INJECTORS
        • 6.3.1.2.5 OTHERS
    • 6.3.2 INJECTABLE DRUG DELIVERY FORMULATIONS
      • 6.3.2.1 CONVENTIONAL DRUG DELIVERY FORMULATIONS
      • 6.3.2.2 NOVEL DRUG DELIVERY FORMULATIONS
      • 6.3.2.3 LONG ACTING INJECTION FORMULATIONS
  • 6.4 OPHTHALMIC DRUG DELIVERY
      • 6.4.1.1 OCULAR DRUG DELIVERY FORMULATIONS
        • 6.4.1.1.1 LIQUID OCULAR DRUG DELIVERY FORMULATIONS
        • 6.4.1.1.1.1 SOLUTIONS
        • 6.4.1.1.1.2 SUSPENSIONS
        • 6.4.1.1.2 SEMI SOLID OCULAR DRUG DELIVERY FORMULATIONS
        • 6.4.1.1.2.1 GELS
        • 6.4.1.1.2.2 OINTMENTS
      • 6.4.1.2 OCULAR DRUG DELIVERY DEVICES
        • 6.4.1.2.1.1 DRUG COATED CONTACT LENSES
        • 6.4.1.2.1.2 OCULAR INSERTS
  • 6.5 NASAL DRUG DELIVERY
    • 6.5.1 NASAL DROPS
    • 6.5.2 NASAL SPRAYS
    • 6.5.3 NASAL POWDERS
    • 6.5.4 NASAL GELS
  • 6.6 TOPICAL DRUG DELIVERY
    • 6.6.1 TRANSDERMAL DRUG DELIVERY DEVICES
      • 6.6.1.1 TRANSDERMAL PATCHES
      • 6.6.1.2 TRANSDERMAL GELS
    • 6.6.2 TRANSDERMAL DRUG DELIVERY FORMULATIONS
      • 6.6.2.1 LIQUID TOPICAL DRUG DELIVERY FORMULATIONS
        • 6.6.2.1.1 SUSPENSIONS
        • 6.6.2.1.2 SOLUTIONS
      • 6.6.2.2 SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS
        • 6.6.2.2.1 OINTMENTS
        • 6.6.2.2.2 CREAMS
        • 6.6.2.2.3 LOTIONS
        • 6.6.2.2.4 GELS
        • 6.6.2.2.5 PASTES
      • 6.6.2.3 SOLID TOPICAL DRUG DELIVERY FORMULATIONS
        • 6.6.2.3.1 POWDER
        • 6.6.2.3.2 SUPPOSITORS
  • 6.7 IMPLANTABLE DRUG DELIVERY
    • 6.7.1 PASSIVE IMPLANTABLE DRUG DELIVERY DEVICES
    • 6.7.2 ACTIVE IMPLANTABLE DRUG DELIVERY DEVICES
  • 6.8 TRANSMUCOSAL DRUG DELIVERY
    • 6.8.1 ORAL TRANSMUCOSAL DRUG DELIVERY
      • 6.8.1.1 BUCCAL DRUG DELIVERY
      • 6.8.1.2 SUBLINGUAL DRUG DELIVERY
    • 6.8.2 OTHER TRANSMUCOSAL DRUG DELIVERY
      • 6.8.2.1 RECTAL TRANSMUCOSAL DRUG DELIVERY
      • 6.8.2.2 VAGINAL TRANSMUCOSAL DRUG DELIVERY
  • 6.9 PULMONARY DRUG DELIVERY
    • 6.9.1 METERED DOSE INHALERS (MDI)
    • 6.9.2 DRY POWDER INHALERS (DPI)
    • 6.9.3 NEBULIZERS
      • 6.9.3.1 JET NEBULIZERS
      • 6.9.3.2 ULTRASONIC NEBULIZERS
      • 6.9.3.3 SOFT MIST NEBULIZERS

7 NORTH AMERICA DRUG DELIVERY MARKET, BY END USER

  • 7.1 OVERVIEW
  • 7.2 HOSPITALS
  • 7.3 HOME HEALTHCARE
  • 7.4 CLINICS
  • 7.5 COMMUNITY HEALTHCARE
  • 7.6 OTHERS

8 NORTH AMERICA DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL

  • 8.1 OVERVIEW
  • 8.2 DIRECT TENDERS
  • 8.3 HOSPITAL PHARMACIES
  • 8.4 PHARMACY STORES
  • 8.5 ONLINE PHARMACY

9 NORTH AMERICA DRUG DELIVERY MARKET, BY GEOGRAPHY

  • 9.1 NORTH AMERICA
    • 9.1.1 U.S.
    • 9.1.2 CANADA
    • 9.1.3 MEXICO

10 NORTH AMERICA DRUG DELIVERY MARKET, COMPANY LANDSCAPE

  • 10.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

11 COMPANY PROFILES

  • 11.1 JOHNSON & JOHNSON SERVICES, INC.
    • 11.1.1 COMPANY SNAPSHOT
    • 11.1.2 REVENUE ANALYSIS
    • 11.1.3 COMPANY SHARE ANALYSIS
    • 11.1.4 PRODUCT PORTFOLIO
    • 11.1.5 RECENT DEVELOPMENTS
  • 11.2 NOVARTIS AG
    • 11.2.1 COMPANY SNAPSHOT
    • 11.2.2 REVENUE ANALYSIS
    • 11.2.3 COMPANY SHARE ANALYSIS
    • 11.2.4 PRODUCT PORTFOLIO
    • 11.2.5 RECENT DEVELOPMENTS
  • 11.3 F. HOFFMANN-LA ROCHE LTD
    • 11.3.1 COMPANY SNAPSHOT
    • 11.3.2 REVENUE ANALYSIS
    • 11.3.3 COMPANY SHARE ANALYSIS
    • 11.3.4 PRODUCT PORTFOLIO
    • 11.3.5 RECENT DEVELOPMENTS
  • 11.4 BAYER AG
    • 11.4.1 COMPANY SNAPSHOT
    • 11.4.2 REVENUE ANALYSIS
    • 11.4.3 COMPANY SHARE ANALYSIS
    • 11.4.4 PRODUCT PORTFOLIO
    • 11.4.5 RECENT DEVELOPMENTS
  • 11.5 PFIZER INC.
    • 11.5.1 COMPANY SNAPSHOT
    • 11.5.2 REVENUE ANALYSIS
    • 11.5.3 COMPANY SHARE ANALYSIS
    • 11.5.4 BRAND PORTFOLIO
    • 11.5.5 RECENT DEVELOPMENTS
  • 11.6 3M
    • 11.6.1 COMPANY SNAPSHOT
    • 11.6.2 REVENUE ANALYSIS
    • 11.6.3 PRODUCT PORTFOLIO
    • 11.6.4 RECENT DEVELOPMENTS
  • 11.7 ANTARES PHARMA
    • 11.7.1 COMPANY SNAPSHOT
    • 11.7.2 REVENUE ANALYSIS
    • 11.7.3 PRODUCT PORTFOLIO
    • 11.7.4 RECENT DEVELOPMENTS
  • 11.8 GLAXOSMITHKLINE PLC
    • 11.8.1 COMPANY SNAPSHOT
    • 11.8.2 REVENUE ANALYSIS
    • 11.8.3 PRODUCT PORTFOLIO
    • 11.8.4 RECENT DEVELOPMENTS
  • 11.9 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.)
    • 11.9.1 COMPANY SNAPSHOT
    • 11.9.2 REVENUE ANALYSIS
    • 11.9.3 PRODUCT PORTFOLIO
    • 11.9.4 RECENT DEVELOPMENTS
  • 11.10 NEMERA
    • 11.10.1 COMPANY SNAPSHOT
    • 11.10.2 PRODUCT PORTFOLIO
    • 11.10.3 RECENT DEVELOPMENTS
  • 11.11 SANOFI
    • 11.11.1 COMPANY SNAPSHOT
    • 11.11.2 REVENUE ANALYSIS
    • 11.11.3 PRODUCT PORTFOLIO
    • 11.11.4 RECENT DEVELOPMENTS

12 QUESTIONNAIRE

13 RELATED REPORTS

LIST OF TABLES

  • TABLE 1 LIST OF FDA APPROVED BIOLOGICS, IN 2016
  • TABLE 2 MOST EXPENSIVE DRUGS IN THE U.S.
  • TABLE 3 MAJOR PRODUCT RECALLS IN THE DRUG DELIVERY MARKET, 2019-2020
  • TABLE 4 LIST OF FDA APPROVED GENERICS, IN 2019
  • TABLE 5 PATENT EXPIRY OF DRUGS, 2019
  • TABLE 6 NORTH AMERICA DRUG DELIVERY MARKET, BY PRODUCT TYPE , 2018-2027 (USD BILLION)
  • TABLE 7 NORTH AMERICA ORAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY REGION, 2018-2027 (USD BILLION)
  • TABLE 8 NORTH AMERICA ORAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY FORM, 2018-2027 (USD BILLION)
  • TABLE 9 NORTH AMERICA SOLID ORAL DRUG IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 10 NORTH AMERICA LIQUID ORAL DRUG IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 11 NORTH AMERICA SEMI SOLID ORAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 12 NORTH AMERICA INJECTABLE DRUG DELIVERY IN DRUG DELIVERY MARKET, BY REGION, 2018-2027 (USD BILLION)
  • TABLE 13 NORTH AMERICA INJECTABLE DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 14 NORTH AMERICA INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 15 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY MATERIAL, 2018-2027 (USD BILLION)
  • TABLE 16 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY PRODUCT TYPE 2018-2027 (USD BILLION)
  • TABLE 17 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY USABILITY, 2018-2027 (USD BILLION)
  • TABLE 18 NORTH AMERICA SELF-INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 19 NORTH AMERICA INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 20 NORTH AMERICA OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY MARKET, BY REGION, 2018-2027 (USD BILLION)
  • TABLE 21 NORTH AMERICA OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 22 NORTH AMERICA OCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY FORM, 2018-2027 (USD BILLION)
  • TABLE 23 NORTH AMERICA LIQUID OCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY TYPE, 2018-2027 (USD BILLION)
  • TABLE 24 NORTH AMERICA SEMI SOLID OCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY TYPE, 2018-2027 (USD BILLION)
  • TABLE 25 NORTH AMERICA OCULAR DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 26 NORTH AMERICA NASAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY REGION, 2018-2027 (USD BILLION)
  • TABLE 27 NORTH AMERICA NASAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 28 NORTH AMERICA TOPICAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY REGION, 2018-2027 (USD BILLION)
  • TABLE 29 NORTH AMERICA TOPICAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 30 NORTH AMERICA TRANSDERMAL DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 31 NORTH AMERICA TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY FORM, 2018-2027 (USD BILLION)
  • TABLE 32 NORTH AMERICA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY TYPE, 2018-2027 (USD BILLION)
  • TABLE 33 NORTH AMERICA SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY TYPE, 2018-2027 (USD BILLION)
  • TABLE 34 NORTH AMERICA SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY TYPE, 2018-2027 (USD BILLION)
  • TABLE 35 NORTH AMERICA IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY MARKET, BY REGION, 2018-2027 (USD BILLION)
  • TABLE 36 NORTH AMERICA IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 37 NORTH AMERICA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY REGION, 2018-2027 (USD BILLION)
  • TABLE 38 NORTH AMERICA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 39 NORTH AMERICA ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 40 NORTH AMERICA OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 41 NORTH AMERICA PULMONARY DRUG DELIVERY IN DRUG DELIVERY MARKET, BY REGION, 2018-2027 (USD BILLION)
  • TABLE 42 NORTH AMERICA PULMONARY DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 43 NORTH AMERICA NEBULIZERS IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 44 NORTH AMERICA DRUG DELIVERY MARKET, BY END USER, 2018-2027 (USD BILLION)
  • TABLE 45 NORTH AMERICA HOPITALS IN DRUG DELIVERY MARKET, BY REGION, 2018-2027 (USD BILLION)
  • TABLE 46 NORTH AMERICA HOME HEALTHCARE IN DRUG DELIVERY MARKET, BY REGION, 2018-2027 (USD BILLION)
  • TABLE 47 NORTH AMERICA CLINICS IN DRUG DELIVERY MARKET, BY REGION, 2018-2027 (USD BILLION)
  • TABLE 48 NORTH AMERICA COMMUNITY HEALTHCARE IN DRUG DELIVERY MARKET, BY REGION, 2018-2027 (USD BILLION)
  • TABLE 49 NORTH AMERICA OTHERS IN DRUG DELIVERY MARKET, BY REGION, 2018-2027 (USD BILLION)
  • TABLE 50 NORTH AMERICA DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
  • TABLE 51 NORTH AMERICA DIRECT TENDERS IN DRUG DELIVERY MARKET, BY REGION, 2018-2027 (USD BILLION)
  • TABLE 52 NORTH AMERICA HOSPITAL PHARMACIES IN DRUG DELIVERY MARKET, BY REGION, 2018-2027 (USD BILLION)
  • TABLE 53 NORTH AMERICA PHARMACY STORES IN DRUG DELIVERY MARKET, BY REGION, 2018-2027 (USD BILLION)
  • TABLE 54 NORTH AMERICA ONLINE PHARMACY IN DRUG DELIVERY MARKET, BY REGION, 2018-2027 (USD BILLION)
  • TABLE 55 NORTH AMERICA DRUG DELIVERY MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
  • TABLE 56 NORTH AMERICA DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2027 (USD BILLION)
  • TABLE 57 NORTH AMERICA ORAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY FORM, 2018-2027 (USD BILLION)
  • TABLE 58 NORTH AMERICA SOLID ORAL DRUGS IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 59 NORTH AMERICA LIQUID ORAL DRUGS IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 60 NORTH AMERICA SEMI-SOLID ORAL DRUGS IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 61 NORTH AMERICA INJECTABLE DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 62 NORTH AMERICA INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 63 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY MATERIAL, 2018-2027 (USD BILLION)
  • TABLE 64 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 65 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY USABILITY, 2018-2027 (USD BILLION)
  • TABLE 66 NORTH AMERICA SELF-INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY USABILITY, 2018-2027 (USD BILLION)
  • TABLE 67 NORTH AMERICA INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 68 NORTH AMERICA OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 69 NORTH AMERICA OCULAR DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 70 NORTH AMERICA OCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY FORM, 2018-2027 (USD BILLION)
  • TABLE 71 NORTH AMERICA LIQUID OCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY TYPE, 2018-2027 (USD BILLION)
  • TABLE 72 NORTH AMERICA SEMI-SOLID OCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY TYPE, 2018-2027 (USD BILLION)
  • TABLE 73 NORTH AMERICA NASAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 74 NORTH AMERICA TOPICAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 75 NORTH AMERICA TRANSDERMAL DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 76 NORTH AMERICA TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY FORM, 2018-2027 (USD BILLION)
  • TABLE 77 NORTH AMERICA SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY TYPE, 2018-2027 (USD BILLION)
  • TABLE 78 NORTH AMERICA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY TYPE, 2018-2027 (USD BILLION)
  • TABLE 79 NORTH AMERICA SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY TYPE, 2018-2027 (USD BILLION)
  • TABLE 80 NORTH AMERICA IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 81 NORTH AMERICA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 82 NORTH AMERICA ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 83 NORTH AMERICA OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 84 NORTH AMERICA PULMONARY DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 85 NORTH AMERICA NEBULIZERS IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 86 NORTH AMERICA DRUG DELIVERY MARKET, BY END USER, 2018-2027 (USD BILLION)
  • TABLE 87 NORTH AMERICA DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
  • TABLE 88 U.S. DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 89 U.S. ORAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY FORM, 2018-2027 (USD BILLION)
  • TABLE 90 U.S. SOLID ORAL DRUGS IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 91 U.S. LIQUID ORAL DRUGS IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 92 U.S. SEMI-SOLID ORAL DRUGS IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 93 U.S. INJECTABLE DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 94 U.S. INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 95 U.S. CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY MATERIAL, 2018-2027 (USD BILLION)
  • TABLE 96 U.S. CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 97 U.S. CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY USABILITY, 2018-2027 (USD BILLION)
  • TABLE 98 U.S. SELF-INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY USABILITY, 2018-2027 (USD BILLION)
  • TABLE 99 U.S. INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 100 U.S. OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 101 U.S. OCULAR DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 102 U.S. OCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY FORM, 2018-2027 (USD BILLION)
  • TABLE 103 U.S. LIQUID OCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY TYPE, 2018-2027 (USD BILLION)
  • TABLE 104 U.S. SEMI-SOLID OCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY TYPE, 2018-2027 (USD BILLION)
  • TABLE 105 U.S. NASAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 106 U.S. TOPICAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 107 U.S. TRANSDERMAL DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 108 U.S. TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY FORM, 2018-2027 (USD BILLION)
  • TABLE 109 U.S. SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY TYPE, 2018-2027 (USD BILLION)
  • TABLE 110 U.S. LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY TYPE, 2018-2027 (USD BILLION)
  • TABLE 111 U.S. SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY TYPE, 2018-2027 (USD BILLION)
  • TABLE 112 U.S. IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 113 U.S. TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 114 U.S. ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 115 U.S. OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 116 U.S. PULMONARY DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 117 U.S. NEBULIZERS IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 118 U.S. DRUG DELIVERY MARKET, BY END USER, 2018-2027 (USD BILLION)
  • TABLE 119 U.S. DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
  • TABLE 120 CANADA DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2027 (USD BILLION)
  • TABLE 121 CANADA ORAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY FORM, 2018-2027 (USD BILLION)
  • TABLE 122 CANADA SOLID ORAL DRUGS IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 123 CANADA LIQUID ORAL DRUGS IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 124 CANADA SEMI-SOLID ORAL DRUGS IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 125 CANADA INJECTABLE DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 126 CANADA INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 127 CANADA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY MATERIAL, 2018-2027 (USD BILLION)
  • TABLE 128 CANADA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 129 CANADA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY USABILITY, 2018-2027 (USD BILLION)
  • TABLE 130 CANADA SELF-INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY USABILITY, 2018-2027 (USD BILLION)
  • TABLE 131 CANADA INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 132 CANADA OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 133 CANADA OCULAR DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 134 CANADA OCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY FORM, 2018-2027 (USD BILLION)
  • TABLE 135 CANADA LIQUID OCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY TYPE, 2018-2027 (USD BILLION)
  • TABLE 136 CANADA SEMI-SOLID OCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY TYPE, 2018-2027 (USD BILLION)
  • TABLE 137 CANADA NASAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 138 CANADA TOPICAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 139 CANADA TRANSDERMAL DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 140 CANADA TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY FORM, 2018-2027 (USD BILLION)
  • TABLE 141 CANADA SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY TYPE, 2018-2027 (USD BILLION)
  • TABLE 142 CANADA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY TYPE, 2018-2027 (USD BILLION)
  • TABLE 143 CANADA SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY TYPE, 2018-2027 (USD BILLION)
  • TABLE 144 CANADA IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 145 CANADA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 146 CANADA ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 147 CANADA OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 148 CANADA PULMONARY DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 149 CANADA NEBULIZERS IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 150 CANADA DRUG DELIVERY MARKET, BY END USER, 2018-2027 (USD BILLION)
  • TABLE 151 CANADA DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)
  • TABLE 152 MEXICO DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2027 (USD BILLION)
  • TABLE 153 MEXICO ORAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY FORM, 2018-2027 (USD BILLION)
  • TABLE 154 MEXICO SOLID ORAL DRUGS IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 155 MEXICO LIQUID ORAL DRUGS IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 156 MEXICO SEMI-SOLID ORAL DRUGS IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 157 MEXICO INJECTABLE DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 158 MEXICO INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 159 MEXICO CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY MATERIAL, 2018-2027 (USD BILLION)
  • TABLE 160 MEXICO CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 161 MEXICO CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY USABILITY, 2018-2027 (USD BILLION)
  • TABLE 162 MEXICO SELF-INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY USABILITY, 2018-2027 (USD BILLION)
  • TABLE 163 MEXICO INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 164 MEXICO OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 165 MEXICO OCULAR DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 166 MEXICO OCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY FORM, 2018-2027 (USD BILLION)
  • TABLE 167 MEXICO LIQUID OCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY TYPE, 2018-2027 (USD BILLION)
  • TABLE 168 MEXICO SEMI-SOLID OCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY TYPE, 2018-2027 (USD BILLION)
  • TABLE 169 MEXICO NASAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 170 MEXICO TOPICAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 171 MEXICO TRANSDERMAL DRUG DELIVERY DEVICES IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 172 MEXICO TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY FORM, 2018-2027 (USD BILLION)
  • TABLE 173 MEXICO SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY TYPE, 2018-2027 (USD BILLION)
  • TABLE 174 MEXICO LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY TYPE, 2018-2027 (USD BILLION)
  • TABLE 175 MEXICO SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY MARKET, BY TYPE, 2018-2027 (USD BILLION)
  • TABLE 176 MEXICO IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 177 MEXICO TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 178 MEXICO ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 179 MEXICO OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 180 MEXICO PULMONARY DRUG DELIVERY IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 181 MEXICO NEBULIZERS IN DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2018-2027 (USD BILLION)
  • TABLE 182 MEXICO DRUG DELIVERY MARKET, BY END USER, 2018-2027 (USD BILLION)
  • TABLE 183 MEXICO DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD BILLION)

LIST OF FIGURES

  • FIGURE 1 NORTH AMERICA DRUG DELIVERY MARKET: SEGMENTATION
  • FIGURE 2 NORTH AMERICA DRUG DELIVERY MARKET: DATA TRIANGULATION
  • FIGURE 3 NORTH AMERICA DRUG DELIVERY MARKET: DROC ANALYSIS
  • FIGURE 4 NORTH AMERICA DRUG DELIVERY MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
  • FIGURE 5 NORTH AMERICA DRUG DELIVERY MARKET : COMPANY RESEARCH ANALYSIS
  • FIGURE 6 NORTH AMERICA DRUG DELIVERY MARKET: INTERVIEW DEMOGRAPHICS
  • FIGURE 7 NORTH AMERICA DRUG DELIVERY MARKET: DBMR MARKET POSITION GRID
  • FIGURE 8 NORTH AMERICA DRUG DELIVERY MARKET: VENDOR SHARE ANALYSIS
  • FIGURE 9 NORTH AMERICA IS EXPECTED TO DOMINATE THE NORTH AMERICA DRUG DELIVERY MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2020 TO 2027
  • FIGURE 10 RISING PREVALENCE OF CHRONIC DISEASES AND NON CHRONIC DISEASES AND GROWTH IN THE DEVELOPMENT OF BIOLOGICS ARE EXPECTED TO BE KEY DRIVING FACTORS IN THE NORTH AMERICA DRUG DELIVERY MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
  • FIGURE 11 ORAL DRUG DELIVERY IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA DRUG DELIVERY MARKET IN 2020 & 2027
  • FIGURE 12 NORTH AMERICA IS THE FASTEST GROWING MARKET FOR DRUG DELIVERY MANUFACTURERS IN THE FORECAST PERIOD OF 2020 TO 2027
  • FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA DRUG DELIVERY MARKET
  • FIGURE 14 NORTH AMERICA DRUG DELIVERY MARKET: BY PRODUCT TYPE, 2019
  • FIGURE 15 NORTH AMERICA DRUG DELIVERY MARKET: BY PRODUCT TYPE, 2019-2027 (USD BILLION)
  • FIGURE 16 NORTH AMERICA DRUG DELIVERY MARKET: BY PRODUCT TYPE, CAGR (2020-2027)
  • FIGURE 17 NORTH AMERICA DRUG DELIVERY MARKET: BY PRODUCT TYPE, LIFELINE CURVE
  • FIGURE 18 NORTH AMERICA DRUG DELIVERY MARKET: BY END USER, 2019
  • FIGURE 19 NORTH AMERICA DRUG DELIVERY MARKET: BY END USER, 2019-2027 (USD BILLION)
  • FIGURE 20 NORTH AMERICA DRUG DELIVERY MARKET: BY END USER, CAGR (2020-2027)
  • FIGURE 21 NORTH AMERICA DRUG DELIVERY MARKET: BY END USER, LIFELINE CURVE
  • FIGURE 22 NORTH AMERICA DRUG DELIVERY MARKET: BY DISTRIBUTION CHANNEL, 2019
  • FIGURE 23 NORTH AMERICA DRUG DELIVERY MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
  • FIGURE 24 NORTH AMERICA DRUG DELIVERY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)
  • FIGURE 25 NORTH AMERICA DRUG DELIVERY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
  • FIGURE 26 NORTH AMERICA DRUG DELIVERY MARKET: SNAPSHOT (2019)
  • FIGURE 27 NORTH AMERICA DRUG DELIVERY MARKET: BY COUNTRY (2019)
  • FIGURE 28 NORTH AMERICA DRUG DELIVERY MARKET: BY COUNTRY (2020 & 2027)
  • FIGURE 29 NORTH AMERICA DRUG DELIVERY MARKET: BY COUNTRY (2019 & 2027)
  • FIGURE 30 NORTH AMERICA DRUG DELIVERY MARKET: BY PRODUCT TYPE (2020-2027)
  • FIGURE 31 NORTH AMERICA DRUG DELIVERY MARKET: COMPANY SHARE 2019 (%)
Back to Top